Ciao a tutti, la intercytex, ha finito la fase 1 del suo programma trichocyte.
Non ho tempo di tradurre tutto ma il succo è che i risultati sono molto incoraggianti.
Dice anche che il piano di commercializzazione prevede di diffondere in un primo tempo la tecnica attraverso i chirurghi, e secondariamente di rendere tutto piu semplice e di estendere la possibilità di applicare la procedura, come succede oggi col botulino.
Ragionevolmente non sarà domani, visto che dopo la fase 1, ci sono la 2 e la 3, e poi (credo) l'approvazione da parte delle varie organizzazioni. Kemp sembra comunque abbia familiarità con la FDA...
Se vi interessa la discussione su hairsite:
http://www.hairsite4.com/dc/dcboard.php?az...22424&mode=full
http://www.sep.co.uk/venturer/profile_intercytex.html
Intercytex, the UK’s first dedicated regenerative medicine company, is stepping increasingly closer to bringing pioneering new treatments for baldness and chronic wounds to market, an achievement which would earn it a place in medical history books.
The Manchester-based company, which commenced operations in 2000, is a world leader in regenerative medicine which concerns repairing or replacing damaged tissue or organs, and is led by scientists with exceptional credentials in the field. Founder and chief executive Dr Paul Kemp previously worked in the United States for Organogenesis Inc where he was one of the principal scientists engaged in research which led to the US Food and Drug Administration’s approval of the first manufactured organ for sale.
Having worked on first generation cell-based therapies, Kemp and his 48 strong team are now developing innovative second generation cell therapies aimed at billion dollar global markets. The company, in which Scottish Equity Partners invested £2 million in 2003, has two lead products. TrichoCyte is a revolutionary hair transplant technology involving the injection of cultured follicular cells into the scalp to induce hair growth.
Millions of bald people spend up to $20,000 on hair treatments each year, adding up to a hefty annual spend of $1.5 billion on hair loss therapies. “There are 54 million people with substantial hair loss in America alone,” says Kemp, who is confident that Intercytex can make a lucrative entry into the market.
He says TrichoCyte involves less pain and discomfort than conventional transplants and there is evidence it is also more effective. “We’re just finishing a Phase I trial in Manc
Non ho tempo di tradurre tutto ma il succo è che i risultati sono molto incoraggianti.
Dice anche che il piano di commercializzazione prevede di diffondere in un primo tempo la tecnica attraverso i chirurghi, e secondariamente di rendere tutto piu semplice e di estendere la possibilità di applicare la procedura, come succede oggi col botulino.
Ragionevolmente non sarà domani, visto che dopo la fase 1, ci sono la 2 e la 3, e poi (credo) l'approvazione da parte delle varie organizzazioni. Kemp sembra comunque abbia familiarità con la FDA...
Se vi interessa la discussione su hairsite:
http://www.hairsite4.com/dc/dcboard.php?az...22424&mode=full
http://www.sep.co.uk/venturer/profile_intercytex.html
Intercytex, the UK’s first dedicated regenerative medicine company, is stepping increasingly closer to bringing pioneering new treatments for baldness and chronic wounds to market, an achievement which would earn it a place in medical history books.
The Manchester-based company, which commenced operations in 2000, is a world leader in regenerative medicine which concerns repairing or replacing damaged tissue or organs, and is led by scientists with exceptional credentials in the field. Founder and chief executive Dr Paul Kemp previously worked in the United States for Organogenesis Inc where he was one of the principal scientists engaged in research which led to the US Food and Drug Administration’s approval of the first manufactured organ for sale.
Having worked on first generation cell-based therapies, Kemp and his 48 strong team are now developing innovative second generation cell therapies aimed at billion dollar global markets. The company, in which Scottish Equity Partners invested £2 million in 2003, has two lead products. TrichoCyte is a revolutionary hair transplant technology involving the injection of cultured follicular cells into the scalp to induce hair growth.
Millions of bald people spend up to $20,000 on hair treatments each year, adding up to a hefty annual spend of $1.5 billion on hair loss therapies. “There are 54 million people with substantial hair loss in America alone,” says Kemp, who is confident that Intercytex can make a lucrative entry into the market.
He says TrichoCyte involves less pain and discomfort than conventional transplants and there is evidence it is also more effective. “We’re just finishing a Phase I trial in Manc
